Clinical Trials
519
Active:13
Completed:94
Trial Phases
6 Phases
Early Phase 1:8
Phase 1:17
Phase 2:54
+3 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (320 trials with phase data)• Click on a phase to view related trials
Not Applicable
183 (57.2%)Phase 2
54 (16.9%)Phase 4
41 (12.8%)Phase 1
17 (5.3%)Phase 3
17 (5.3%)Early Phase 1
8 (2.5%)Study of YOLT-202 in the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)
Not Applicable
Active, not recruiting
- Conditions
- Alpha-1 Antitrypsin Deficiency (AATD)
- Interventions
- First Posted Date
- 2025-09-26
- Last Posted Date
- 2025-09-26
- Lead Sponsor
- RenJi Hospital
- Target Recruit Count
- 18
- Registration Number
- NCT07193615
- Locations
- 🇨🇳
Ren Ji Hospital Affiliated to Shanghai Jiao Tong University, Shanghai, China
PNB Anesthesia Improves Older Patients' Postoperative Early Recovery Outcomes After Total Hip Arthroplasty
Completed
- Conditions
- Total Hip Arthroplasty (THA)Femoral Neck Fractures
- First Posted Date
- 2025-09-09
- Last Posted Date
- 2025-09-09
- Lead Sponsor
- RenJi Hospital
- Target Recruit Count
- 516
- Registration Number
- NCT07163598
- Locations
- 🇨🇳
RenjiH, Shanghai, Shanghai Municipality, China
Efficacy and Safety of Tranexamic Acid in Adult Liver Transplantation---ESTA Trial
Not Applicable
Not yet recruiting
- Conditions
- Liver TransplantationTranexamic AcidEnd-stage Liver Disease (ESLD)
- Interventions
- Drug: 0.9 % saline
- First Posted Date
- 2025-09-05
- Last Posted Date
- 2025-09-05
- Lead Sponsor
- RenJi Hospital
- Target Recruit Count
- 1546
- Registration Number
- NCT07157631
Continuous Effect Of Rehabilitation Training On Pulmonary Arterial Hypertension Patients
Not Applicable
Recruiting
- Conditions
- Pulmonary Hypertension
- First Posted Date
- 2025-09-02
- Last Posted Date
- 2025-09-02
- Lead Sponsor
- RenJi Hospital
- Target Recruit Count
- 104
- Registration Number
- NCT07149935
- Locations
- 🇨🇳
Renji Hospital, Shanghai, Shanghai Municipality, China
A Clinical Study Evaluating the Efficacy and Safety of Disitamab Vedotin Combined With PD-1 Inhibitor and Radiotherapy as Bladder-preserving Therapy in Patients With Localized HER2-high Expressing Muscle-invasive Bladder Urothelial Carcinoma Following Maximal Transurethral Resection
Not Applicable
Not yet recruiting
- Conditions
- Bladder (Urothelial, Transitional Cell) Cancer
- Interventions
- First Posted Date
- 2025-08-26
- Last Posted Date
- 2025-08-26
- Lead Sponsor
- RenJi Hospital
- Target Recruit Count
- 45
- Registration Number
- NCT07142200
- Locations
- 🇨🇳
Renji Hospital, Shanghai Jiaotong University School of Medecine, Shanghai, Shanghai Municipality, China
- Prev
- 1
- 2
- 3
- 4
- 5
- 104
- Next
News
Lenvatinib-Tislelizumab Combo Shows Promising 93% Response Rate in Rare Hereditary Kidney Cancer
Phase 2 study demonstrates remarkable 93.3% objective response rate for lenvatinib plus tislelizumab in treating fumarate hydratase-deficient renal cell carcinoma, with 20% achieving complete response.